Akorn Recalls Prednisolone Sodium Phosphate Oral Solution Due to Discoloration
Akorn, Inc. is recalling specific lots of Prednisolone Sodium Phosphate Oral Solution because the product failed a color test.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as unlikely to cause adverse health consequences. The issue is a cosmetic defect (discoloration) with no reported injuries.
Plain-English summary
Akorn, Inc. is recalling 17,424 bottles of Prednisolone Sodium Phosphate Oral Solution, 5 mg/5 mL, 120 mL. The affected product is identified by NDC 50383-040-04 and includes Lot numbers 365566 and 365568. The recall was initiated because the product produced an Out of Specification (OOS) result for the APHA Color Test, indicating discoloration.
The affected medication was distributed nationwide in the USA. The source text does not report any illnesses or injuries associated with this recall.
Consumers should check their medication for the specific NDC and lot numbers listed above. If the product matches the recalled items, they should contact their pharmacist or healthcare provider for guidance on disposal or replacement.
The recalled product
- Product
- Prednisolone Sodium Phosphate Oral Solution, 5 mg/5 mL, 120 mL Bottle, Rx only, HI-TECH PHARMACAL CO., INC., Amityville, NY 11701. NDC: 50383-040-04
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Oral Solution
- Hazard
- Affected units
- 17,424
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 365566
- 365568
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · discoloration
See all →- SevereShilpa Medicare Recalls Discolored Pemetrexed Injection Vials
FDA (Drugs) · 2026-08-26
- ModerateShilpa Medicare Recalls Discolored PEMRYDI RTU Injection Vials
FDA (Drugs) · 2026-08-26
- ModeratePantoprazole Sodium Tablets Recalled for Discoloration Issues
FDA (Drugs) · 2026-04-29
- ModerateTavaborole topical solution recalled from three lots because of discoloration
FDA (Drugs) · 2025-10-22
- ModerateAcetaminophen injection containers recalled after discoloration found in one lot
FDA (Drugs) · 2025-09-03